Clinical Trial Update: Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the dose-dependent effects of low-dose interleukin-2 in individuals with Type 1 diabetes, reporting safety and immunological…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Proleukin (aldesleukin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Type 1 Diabetes | Phase 1, Phase 2 | Status: COMPLETED